Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis

Liver International

Volumn 24, Issue 3, 2004, Pages 187-193

  Corpechot, Christophe ^a   Poujol Robert, Armelle ^a   Wendum, Dominique ^a   Galotte, Marie ^a   Chrétien, Yves ^b   Poupon, Renée Eugénie ^b   Poupon, Raoul ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

Author keywords

Biliary liver cirrhosis; Biological markers; Hyaluronan; Sensitivity; Specificity; Ursodeoxycholic acid

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; HYALURONIC ACID; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STAGING;

EID: 3142699968     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0918.x     Document Type: Article

References (23)

1. Heathcote E J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31: 1005-13.
2. Poupon R E, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
3. Lindor K D, Dickson E R, Baldus W P, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
4. Heathcote E J, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
5. Combes B, Carithers R L Jr., Maddrey W C, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-66.
6. Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000; 32: 561-6.
7. Corpechot C, Carrat F, Bonnand A M, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.
8. Poupon R E, Lindor K D, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
9. Lindor K D, Poupon R, Heathcote E J, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000; 355: 657-8.
10. Bonnand A M, Heathcote E J, Lindor K D, et al. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999; 29: 39-43.
11. Kilmurry M R, Heathcote E J, Cauch-Dudek K, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23: 1148-53.
12. Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-8.
13. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
14. Degott C, Zafrani E S, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29: 1007-12.
15. Poupon R, Chazouilleres O, Balkau B, et al. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. J Hepatol 1999; 30: 408-12.
16. Joshi S, Cauch-Dudek K, Wanless I, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35: 409-13.
17. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
18. Guéchot J, Poupon R, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-93.
19. Poupon R E, Balkau B, Guechot J, et al. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994; 19: 635-40.
20. Gordon S C. Diagnostic criteria, clinical manifestations and natural history of autoimmune hepatitis. In: Krawitt E L, Wiesner R H, Nishioka M, eds. Autoimmune Liver diseases. Amsterdam: Elsevier, 1998; 343-60.
21. Levy C, Lindor K. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2003; 38: S24-37.
22. Leuschner M, Dietrich C F, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000; 46: 121-6.
23. Prince M I, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 1044-51.